<p>The disclosure provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). Further disclosed are humanized monoclonal antibody comprising three light chain Kabat CDRs and three heavy chain Kabat CDRs with framwork modifications. These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases.</p>
申请公布号
WO2012109280(A3)
申请公布日期
2013.11.14
申请号
WO2012US24195
申请日期
2012.02.07
申请人
NEOTOPE BIOSCIENCES LIMITED;SCHENK, DALE, B.;NIJJAR, TARLOCHAN, S.;PAYNE, PHILIP, W.;BARBOUR, ROBIN
发明人
SCHENK, DALE, B.;NIJJAR, TARLOCHAN, S.;PAYNE, PHILIP, W.;BARBOUR, ROBIN